Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: Preliminary findings of a pilot study

International Ophthalmology

Volumn 29, Issue 4, 2009, Pages 213-224

  Ziemssen, Focke ^a   Zhu, Qi ^a,b   Peters, Swaantje ^a   Grisanti, Salvatore ^a   El Wardani, Mohammed ^a   Szurman, Peter ^a   Bartz Schmidt, Karl U ^a   Ziemssen, Tjalf ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Anti VEGF therapy; Nocturnal dipping; Vascular endothelial growth factor

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASCULOTROPIN A;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CENTRAL RETINA VEIN OCCLUSION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; HEART HEMODYNAMICS; HEART RATE; HUMAN; HYPERTENSION; PILOT STUDY; PROTEIN BLOOD LEVEL; PULSE PRESSURE; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CHOROIDAL NEOVASCULARIZATION; CIRCADIAN RHYTHM; HEART RATE; HUMANS; HYPERTENSION; INJECTIONS; MIDDLE AGED; PILOT PROJECTS; RETINA; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 68249149799     PISSN: 01655701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10792-008-9221-7     Document Type: Article

References (45)

1. Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, Ross J, Jin H (1996) Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27(6):838-844
2. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER (2003) The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107(10):1359-1365
3. Yang JC (2004) Bevacizumab for patients with metastatic renal cancer: An update. Clin Cancer Res 10(18 Pt 2):6367S-6370S
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335-2342
5. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ (2005) Recommendations for blood prBssure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111(5):697-716
6. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26(8):859-870
7. Kernt M, Neubauer A, Kamik A (2007) Intravitreal bevacizumab (Avastin) treatment is dafe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85:119-120
8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419-1431
9. Prisant LM (1995) Ambulatory blood pressure monitoring in the diagnosis of hypertension. Cardiol Clin 13(4):479-490
10. Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB (1999) Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med 131(8):564-572
11. Angeli F, Verdecchia P, Gattobigio R, Sardone M, Reboldi G (2005) White-coat hypertension in adults. Blood Press Monit 10(6):301-305
12. White WB, Berson AS, Robbins C, Jamieson MJ, Prisant LM, Roccella E, Sheps SG (1993) National standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers. Hypertension 21(4):504-509
13. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM, Ryan AM (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27(5):536-544
14. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48(6):2814-2823
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 289(19):2560-2572
16. Yarows SA, Khoury S, Sowers JR (1994) Cost effectiveness of 24-hour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension. Am J Hypertens 7(5):464-468
17. James GD, Pickering TG, Yee LS, Harshfield GA, Riva S, Laragh JH (1988) The reproducibility of average ambulatory, home, and clinic pressures. Hypertension 11(6 Pt 1):545-549
18. Fotherby MD, Potter JF (1993) Reproducibility of ambulatory and clinic blood pressure measurements in elderly hypertensive subjects. J Hypertens 11(5):573-579
19. Staessen JA, Thijs L, Clement D, Davidson C, Fagard R, Lehtonen A, Mancia G, Palatini P, O'Brien ET, Parati G (1994) Ambulatory pressure decreases on long-term placebo treatment in older patients with isolated systolic hypertension. Syst-Eur Investigators. J Hypertens 12(9):1035-1039
20. Palatini P, Mormino P, Canali C, Santonastaso M, De Venuto G, Zanata G, Pessina AC (1994) Factors affecting ambulatory blood pressure reproducibility. Results of the HARVEST Trial. Hypertension and ambulatory recording venetia study. Hypertension 23(2):211-216
21. Mansoor GA, McCabe EJ, White WB (1994) Long-term reproducibility of ambulatory blood pressure. J Hypertens 12(6):703-708
22. Ceyhan M, Gunaydin S, Yorgancioglu C, Zorlutuna Y, Uluoglu C, Zengil H (2003) Comparison of circadian rhythm characteristics of blood pressure and heart rate in patients before and after elective coronary artery bypass surgery. Chronobiol Int 20(2):337-349
23. Brigden G, Broadhurst P, Cashman P, Raftery EB (1990) Effects of noninvasive ambulatory blood pressure measuring devices on blood pressure. Am J Cardiol 66(19):1396-1398
24. Parati G, Pomidossi G, Casadei R, Malaspina D, Colombo A, Ravogli A, Mancia G (1985) Ambulatory blood pressure monitoring does not interfere with the haemodynamic effects of sleep. J Hypertens Suppl 3(2):S107-S109
25. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, Porcellati C (1990) Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81(2):528-536
26. Rizzoni D, Muiesan ML, Montani G, Zulli R, Calebich S, Agabiti-Rosei E (1992) Relationship between initial cardiovascular structural changes and daytime and nighttime blood pressure monitoring. Am J Hypertens 5(3):180-186
27. Weir MR, Blantz RC (2003) Blood pressure and cardiovascular risks: implications of the presence or absence of a nocturnal dip in blood pressure. Curr Opin Nephrol Hypertens 12(1):57-60
28. Safar ME (2004) Pulse pressure, heart rate, and drug treatment of hypertension. Curr Hypertens Rep 6(3):190-194
29. Waldstein SR, Siegel EL, Lefkowitz D, Maier KJ, Brown JR, Obuchowski AM, Katzel LI (2004) Stress-induced blood pressure reactivity and silent cerebrovascular disease. Stroke 35(6):1294-1298
30. Cuspidi C, Meani S, Lonati L, Fusi V, Valerio C, Sala C, Magnaghi G, Maisaidi M, Zanchetti A (2006) Short term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients. J Hypertens 24:647-653
31. Cuspidi C, Meani S, Valerio C, Sala C, Fusi V, Massaidi M, Zanchetti A, Mancia G (2007) Reproducibility of dipping/nondipping pattern in untreated essential hypertensive patients: Impact of sex and age. Blood Press Monit 12:101-106
32. Stenehjem AE, Os I (2004) Reproducibility of blood pressure variability, white-coat effect and dipping pattern in untreated, uncomplicated and newly diagnosed essential hypertension. Blood Press 13:214-224
33. Fung AE, Rosenfeld PJ, Reichel E (2006) The international intravitreal bevacizumab safety survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol 90(11):1344-1349
34. Scappati FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232-1239
35. Ziemssen F, Luke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU (2007) Safety monitoring in bevacizumab (Avastin) treatment: Retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol
36. Genentech Inc (2004) Avastin™ (bevacizumab) for intravenous use [Package insert]. South San Francisco CA
37. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1):60-65
38. Zhu X, Shenhong W, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 49(2):186-193
39. Csaky KG, Gordiyenko N, Rabena MG, Avery RL (2008) Pharmakokinetics of intravitreal bevacizumab in humans. Curr Opin Ophthalmol (in press)
40. Assy N, Paizi N, Gaitini B, Baruch Y, Spira G (1999) Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. World J Gastroenterol 5(4):296-300
41. Sane DC, Anton L, Brosnihan KB (2004) Angiogenic growth factors and hypertension. Angiogenesis 7(3):193-201
42. Rosiak J, Sadowski L (2005) Hypertension associated with bevacizumab. Clin J Oncol Nurs 9(4):407-411
43. Wong T, Mitchell P (2007) The eye in hypertension. Lancet 369(9559):425-435
44. Dafer RM, Schneck M, Friberg TR, Jay WM (2007) Intravitreal ranibizumab and bevacizumab: A review of reisk. Semin Ophthalmol 22(3):201-204
45. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46(2):726-733